These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38229252)

  • 21. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys.
    Cinislioglu AE; Demirdogen SO; Cinislioglu N; Altay MS; Sam E; Akkas F; Tor IH; Aydin HR; Karabulut I; Ozbey I
    Urology; 2022 Jan; 159():16-21. PubMed ID: 34626600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
    Henning JD; Karamchandani JM; Bonachea LA; Bunker CH; Patrick AL; Jenkins FJ
    Prostate; 2017 May; 77(6):617-624. PubMed ID: 28117495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis.
    Hochreiter WW
    Andrologia; 2008 Apr; 40(2):130-3. PubMed ID: 18336465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
    Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
    J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical assessment of free serum prostate specific antigen (PSA)].
    Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
    Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of age-specific normal ranges for prostate-specific antigen.
    Speights VO; Brawn PN; Foster DM; Spiekerman AM; Kuhl D; Riggs MW
    Urology; 1995 Mar; 45(3):454-7; discussion 457-8. PubMed ID: 7533457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice.
    Rommel FM; Agusta VE; Breslin JA; Huffnagle HW; Pohl CE; Sieber PR; Stahl CA
    J Urol; 1994 Jan; 151(1):88-93. PubMed ID: 7504748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
    Ornstein DK; Smith DS; Humphrey PA; Catalona WJ
    J Urol; 1998 Apr; 159(4):1234-7. PubMed ID: 9507843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
    Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
    Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of prostatic biopsy on free-to-total prostate-specific antigen ratio in patients with prostate cancer.
    Furuya Y; Akakura K; Ichikawa T; Masai M; Igarashi T; Ito H
    Int J Urol; 2000 Feb; 7(2):49-53. PubMed ID: 10710247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma.
    Zanetti G; Trinchieri A; Del Nero A; Montanari E; Cogni M; Colombo F; Buzzetti V; Austoni E
    Eur Urol; 1992; 21 Suppl 1():96-8. PubMed ID: 1385139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in japanese prostate cancer patients with slightly elevated serum PSA levels.
    Kuriyama M; Uno H; Watanabe H; Yamanaka H; Saito Y; Shida K
    Jpn J Clin Oncol; 1999 Dec; 29(12):617-22. PubMed ID: 10721944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of prostate-specific antigen and digital rectal examination in the detection of prostate cancer.
    Yamamoto M; Hibi H; Miyake K
    Int J Urol; 1994 Mar; 1(1):74-7. PubMed ID: 7543009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature.
    Safa AA; Reese DM; Carter DM; Phillipson J; Smith R; Dougherty S
    Am J Clin Oncol; 1998 Aug; 21(4):323-6. PubMed ID: 9708626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pitfalls in interpreting prostate specific antigen velocity.
    Kadmon D; Weinberg AD; Williams RH; Pavlik VN; Cooper P; Migliore PJ
    J Urol; 1996 May; 155(5):1655-7. PubMed ID: 8627846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.